Antidiabetic Effects of Resveratrol: The Way Forward in Its Clinical Utility

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Oyenihi, Omolola R ^a   Oyenihi, Ayodeji B ^b   Adeyanju, Anne A ^a   Oguntibeju, Oluwafemi O ^c  

^a BOWEN UNIVERSITY   (Nigeria)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

RESVERATROL; ANTIDIABETIC AGENT; STILBENE DERIVATIVE;

ANTIDIABETIC ACTIVITY; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; HUMAN; NONHUMAN; REVIEW; ANIMAL;

ANIMALS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; STILBENES;

EID: 85008656035     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/9737483     Document Type: Review

References (143)

1. A. Lançon, N. Hanet, B. Jannin et al., "Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes, " DrugMetabolism and Disposition, vol. 35, no. 5, pp. 699-703, 2007.
2. U. Stervbo, O. Vang, and C. Bonnesen, "Areviewof the content of the putative chemopreventive phytoalexin resveratrol in red wine, " Food Chemistry, vol. 101, no. 2, pp. 449-457, 2007.
3. S. Bastianetto, C. Ménard, and R. Quirion, "Neuroprotective action of resveratrol, " Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1852, no. 6, pp. 1195-1201, 2015.
4. B. Catalgol, S. Batirel, Y. Taga, and N. K. Ozer, "Resveratrol: french paradox revisited, " Frontiers in Pharmacology, vol. 3, article 141, 2012.
5. G. A. Potter, L. H. Patterson, E. Wanogho et al., "The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1b1, " British Journal of Cancer, vol. 86, no. 5, pp. 774-778, 2002.
6. K. Ashikawa, S. Majumdar, S. Banerjee, A. C. Bharti, S. Shishodia, and B. B. Aggarwal, "Piceatannol inhibits TNFinduced NF-κB activation and NF-κB-mediated gene expression through suppression of IκBα kinase and p65 phosphorylation, " Journal of Immunology, vol. 169, no. 11, pp. 6490-6497, 2002.
7. T. Wieder, A. Prokop, B. Bagci et al., "Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts, " Leukemia, vol. 15, no. 11, pp. 1735-1742, 2001.
8. Z. Ovesná and K. Horváthová-Kozics, "Structure-activity relationship of trans-resveratrol and its analogues, " Neoplasma, vol. 52, no. 6, pp. 450-455, 2005.
9. K. R. Patel, V. A. Brown, D. J. L. Jones et al., "Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients, " Cancer Research, vol. 70, no. 19, pp. 7392-7399, 2010.
10. A. Quincozes-Santos, L. D. Bobermin, A. Latini et al., "Resveratrol protects C6 astrocyte cell line against hydrogen peroxideinduced oxidative stress through heme oxygenase 1, " PLoSONE, vol. 8, no. 5, Article IDe64372, 2013.
11. J. L. Bitterman and J. H. Chung, "Metabolic effects of resveratrol: addressing the controversies, " Cellular and Molecular Life Sciences, vol. 72, no. 8, pp. 1473-1488, 2015.
12. V. Ciddi and D. Dodda, "Therapeutic potential of resveratrol in diabetic complications: in vitro and in vivo studies, " Pharmacological Reports, vol. 66, no. 5, pp. 799-803, 2014.
13. B. N. M. Zordoky, I. M. Robertson, and J. R. B. Dyck, "Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases, " Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1852, no. 6, pp. 1155-1177, 2015.
14. M. M. Poulsen, K. Fjeldborg, M. J. Ornstrup, T. N. Kjær, M. K. Nøhr, and S. B. Pedersen, "Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes, " Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1852, no. 6, pp. 1124-1136, 2015.
15. B. Jiang, L. Guo, B.-Y. Li et al., "Resveratrol attenuates early diabetic nephropathy by down-regulating glutathione StransferasesMu in diabetic rats, " Journal ofMedicinal Food, vol. 16, no. 6, pp. 481-486, 2013.
16. J. K. Bhatt, S. Thomas, and M. J. Nanjan, "Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus, " Nutrition Research, vol. 32, no. 7, pp. 537-541, 2012.
17. D. O. Kennedy, E. L. Wightman, J. L. Reay et al., "Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation, " American Journal of Clinical Nutrition, vol. 91, no. 6, pp. 1590-1597, 2010.
18. C. Rivière, T. Richard, X. Vitrac, J.-M. Mérillon, J. Valls, and J.-P. Monti, "New polyphenols active on β-amyloid aggregation, " Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 2, pp. 828-831, 2008.
19. C.-C. Chang, C.-Y. Chang, Y.-T. Wu, J.-P. Huang, T.-H. Yen, and L.-M. Hung, "Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase, " Journal of Biomedical Science, vol. 18, no. 1, article no. 47, 2011.
20. S. Kubota, Y. Ozawa, T. Kurihara et al., "Roles of AMP-activated protein kinase in diabetes-induced retinal inflammation, " Investigative Ophthalmology and Visual Science, vol. 52, no. 12, pp. 9142-9148, 2011.
21. A. S. Yar, S. Menevse, and E. Alp, "The effects of resveratrol on cyclooxygenase-1 and-2, nuclear factor kappa beta, matrix metalloproteinase-9, and sirtuin 1 mRNA expression in hearts of streptozotocin-induced diabetic rats, " Genetics andMolecular Research, vol. 10, no. 4, pp. 2962-2975, 2011.
22. R. Guo, B. Liu, K. Wang, S. Zhou, W. Li, and Y. Xu, "Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-κB pathway, " Diabetes and Vascular Disease Research, vol. 11, no. 2, pp. 92-102, 2014.
23. B. Wang, Q. Yang, Y.-Y. Sun et al., "Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice, " Journal of Cellular and Molecular Medicine, vol. 18, no. 8, pp. 1599-1611, 2014.
24. P. Palsamy and S. Subramanian, "Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling, " Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1812, no. 7, pp. 719-731, 2011.
25. F. Xu, Y. Wang, W. Cui et al., "Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-κB pathway, " International Journal of Endocrinology, vol. 2014, Article ID 289327, 9 pages, 2014.
26. IDF, IDF Diabetes Atlas, 7th edition, 2015.
27. M. J. Fowler, "Microvascular and macrovascular complications of diabetes, " Clinical Diabetes, vol. 26, no. 2, pp. 77-82, 2008.
28. American Diabetes Association, "Diagnosis and classification of diabetes mellitus, " Diabetes Care, vol. 32, supplement 1, pp. S62-S67, 2009.
29. S. E. Kahn, "The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes, " Diabetologia, vol. 46, no. 1, pp. 3-19, 2003.
30. J. C. Michael, M. C. James, and V. K. Robbins, "Pathalogic basis of disease, " in The Pancreas, pp. 902-929, Harcourt, 6th edition, 2000.
31. A. B. Oyenihi, A. O. Ayeleso, E. Mukwevho, and B. Masola, "Antioxidant strategies in themanagement of diabetic neuropathy, " BioMed Research International, vol. 2015, Article ID515042, 15 pages, 2015.
32. T. Szkudelski and K. Szkudelska, "Resveratrol and diabetes: from animal to human studies, " Biochimica et biophysica acta, vol. 1852, no. 6, pp. 1145-1154, 2015.
33. A. Ambade and P. Mandrekar, "Oxidative stress and inflammation: essential partners in alcoholic liver disease, " International Journal ofHepatology, vol. 2012, Article ID853175, 9 pages, 2012.
34. B. Halliwell and M. Whiteman, "Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?" British Journal of Pharmacology, vol. 142, no. 2, pp. 231-255, 2004.
35. S. D. M. Bandeira, L. J. S. da Fonseca, G. D. S. Guedes, L. A. Rabelo, M. O. F. Goulart, and S. M. L. Vasconcelos, "Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus, " International Journal of Molecular Sciences, vol. 14, no. 2, pp. 3265-3284, 2013.
36. S. Z. Hasnain, J. B. Prins, and M. A. McGuckin, "Oxidative and endoplasmic reticulum stress in beta-cell dysfunction in diabetes, " Journal of Molecular Endocrinology, vol. 56, no. 2, pp. R33-R54, 2016.
37. F. Giacco and M. Brownlee, "Oxidative stress and diabetic complications, " Circulation Research, vol. 107, no. 9, pp. 1058-1070, 2010.
38. J. Styskal, H. Van Remmen, A. Richardson, and A. B. Salmon, "Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models?" Free Radical Biology and Medicine, vol. 52, no. 1, pp. 46-58, 2012.
39. P. Bansal and R. Kakkar, "Resveratrol: a polyphenol with multiple health benefits, " International Journal of Pharmaceutics and Drug Analysis, vol. 2, no. 3, pp. 174-191, 2014.
40. S. K. Biswas, "Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox?" OxidativeMedicine and Cellular Longevity, vol. 2016, Article ID 5698931, 9 pages, 2016.
41. J. M. Forbes and M. E. Cooper, "Mechanisms of diabetic complications, " Physiological Reviews, vol. 93, no. 1, pp. 137-188, 2013.
42. L. Wu, Y. Zhang, X. Ma, N. Zhang, and G. Qin, "The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats, " Molecular Biology Reports, vol. 39, no. 9, pp. 9085-9093, 2012.
43. H. Elbe, N. Vardi, M. Esrefoglu, B. Ates, S. Yologlu, and C. Taskapan, "Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats, " Human and Experimental Toxicology, vol. 34, no. 1, pp. 100-113, 2015.
44. A. Kumar, R. K. Kaundal, S. Iyer, and S. S. Sharma, "Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy, " Life Sciences, vol. 80, no. 13, pp. 1236-1244, 2007.
45. A. Kumar, G. Negi, and S. S. Sharma, "Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms, " Current Medicinal Chemistry, vol. 20, no. 36, pp. 4640-4645, 2013.
46. J. Hua, K. I. Guerin, J. Chen et al., "Resveratrol inhibits pathologic retinal neovascularization in Vldlr-/- mice, " Investigative Ophthalmology and Visual Science, vol. 52, no. 5, pp. 2809-2816, 2011.
47. Y. H. Kim, Y. S. Kim, G. S. Roh, W. S. Choi, and G. J. Cho, "Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas, " Acta Ophthalmologica, vol. 90, no. 1, pp. e31-e37, 2012.
48. F. G. Soufi, D. Mohammad-nejad, and H. Ahmadieh, "Resveratrol improves diabetic retinopathy possibly through oxidative stress-nuclear factor κB-apoptosis pathway, " Pharmacological Reports, vol. 64, no. 6, pp. 1505-1514, 2012.
49. O. M. A. Allah and F. El-Debakey, "Prophylactic resveratrol and telmisartan combination ameliorates experimentallyinduced diabetic nephropathy in rats, focus on the pro-sclerotic cytokine, transforming growth factor-β1 (TGF-β1), " The Medical Journal of Cairo University, vol. 78, no. 2, 2010.
50. R. K. Vella, C. Pullen, F. R. Coulson, and A. S. Fenning, "Resveratrol prevents cardiovascular complications in the SHR/STZ rat by reductions in oxidative stress and inflammation, " BioMed Research International, vol. 2015, Article ID 918123, 8 pages, 2015.
51. B. Turan, E. Tuncay, and G. Vassort, "Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies, " Journal of Bioenergetics and Biomembranes, vol. 44, no. 2, pp. 281-296, 2012.
52. M. Mohammadshahi, F. Haidari, and F. G. Soufi, "Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress, " Cardiology Journal, vol. 21, no. 1, pp. 39-46, 2014.
53. N. Hamadi, A. Mansour, M.H. Hassan, F. Khalifi-Touhami, and O. Badary, "Ameliorative effects of resveratrol on liver injury in streptozotocin-induced diabetic rats, " Journal of Biochemical and Molecular Toxicology, vol. 26, no. 10, pp. 384-392, 2012.
54. M. A. Hussein and H. A. El-Maksoud, "Biochemical effects of Resveratrol and curcumin combination on obese diabetic rats, " Molecular & Clinical Pharmacology, vol. 4, no. 1, pp. 1-10, 2013.
55. J. L. Fiori, Y.-K. Shin, W. Kim et al., "Resveratrol prevents β-cell dedifferentiation in nonhuman primates given a high-fat/highsugar diet, " Diabetes, vol. 62, no. 10, pp. 3500-3513, 2013.
56. C. R. Ku, H. J. Lee, S. K. Kim, E. Y. Lee, M.-K. Lee, and E. J. Lee, "Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic β-cell and the cleavage of poly (ADP-ribose) polymerase, " Endocrine Journal, vol. 59, no. 2, pp. 103-109, 2012.
57. C.-C. Chang, M.-H. Yang, H.-C. Tung et al., "Resveratrol exhibits differential protective effects on fast-and slow-twitch muscles in streptozotocin-induced diabetic rats, " Journal of Diabetes, vol. 6, no. 1, pp. 60-67, 2014.
58. H.-C. Su, L.-M. Hung, and J.-K. Chen, "Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocininduced diabetic rats, " American Journal of Physiology-Endocrinology andMetabolism, vol. 290, no. 6, pp. E1339-E1346, 2006.
59. S.V. Penumathsa, M. Thirunavukkarasu, L. Zhan et al., "Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium, " Journal of Cellular and Molecular Medicine, vol. 12, no. 6, pp. 2350-2361, 2008.
60. K. H. Chen, M. L. Cheng, Y. H. Jing, D. T. Chiu, M. S. Shiao, and J. K. Chen, "Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats, " The American Journal of Physiology-Endocrinology and Metabolism, vol. 301, no. 5, pp. E853-E863, 2011.
61. D. M. Nathan, M. B. Davidson, R. A. DeFronzo et al., "Impaired fasting glucose and impaired glucose tolerance: implications for care, " Diabetes Care, vol. 30, no. 3, pp. 753-759, 2007.
62. J.A. Baur, K. J. Pearson, N. L. Price et al., "Resveratrol improves health and survival of mice on a high-calorie diet, " Nature, vol. 444, no. 7117, pp. 337-342, 2006.
63. M. Lagouge, C. Argmann, Z. Gerhart-Hines et al., "Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α, " Cell, vol. 127, no. 6, pp. 1109-1122, 2006.
64. Y.-E. Lee, J.-W. Kim, E.-M. Lee et al., "Chronic resveratrol treatment protects pancreatic islets against oxidative stress in db/db mice, " PLoS ONE, vol. 7, no. 11, Article ID e50412, 2012.
65. M.-S. Beaudoin, L. A. Snook, A. M. Arkell, J. A. Simpson, G. P. Holloway, and D. C. Wright, "Resveratrol supplementation improves white adipose tissue function in a depot-specific manner in Zucker diabetic fatty rats, " American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 305, no. 5, pp. R542-R551, 2013.
66. J.-H. Um, S.-J. Park, H. Kang et al., "AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol, " Diabetes, vol. 59, no. 3, pp. 554-563, 2010.
67. J. Marchal, S. Blanc, J. Epelbaum, F. Aujard, and F. Pifferi, "Effects of chronic calorie restriction or dietary resveratrol supplementation on insulin sensitivity markers in a primate, microcebusmurinus, " PLoSONE, vol. 7, no. 3, Article IDe34289, 2012.
68. J. R. Zierath and Y. Kawano, "The effect of hyperglycaemia on glucose disposal and insulin signal transduction in skeletal muscle, " Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 17, no. 3, pp. 385-398, 2003.
69. D. Pitocco, F. Zaccardi, E. Di Stasioet al., "Oxidative stress, nitric oxide, and diabetes, " Review of Diabetic Studies, vol. 7, no. 1, pp. 15-25, 2010.
70. M. Thirunavukkarasu, S. V. Penumathsa, S. Koneru et al., "Resveratrol alleviates cardiac dysfunction in streptozotocininduced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase, " FreeRadical Biology andMedicine, vol. 43, no. 5, pp. 720-729, 2007.
71. A. González-Rodríguez, B. Santamaría, J. A. Mas-Gutierrez et al., "Resveratrol treatment restores peripheral insulin sensitivity in diabetic mice in a sirt1-independent manner, " Molecular Nutrition and Food Research, vol. 59, no. 8, pp. 1431-1442, 2015.
72. H. Moridi, J. Karimi, N. Sheikh et al., "Resveratrol-dependent down-regulation of receptor for advanced glycation endproducts and oxidative stress in kidney of rats with diabetes, " International Journal of Endocrinology and Metabolism, vol. 13, no. 2, Article ID e23542, 2015.
73. M. Khazaei, J. Karimi, N. Sheikh et al., "Effects of resveratrol on receptor for advanced glycation end products (RAGE) expression and oxidative stress in the liver of rats with type 2 diabetes, " Phytotherapy Research, vol. 30, no. 1, pp. 66-71, 2016.
74. N. Chaudhary and P. T. Pfluger, "Metabolic benefits from Sirt1 and Sirt1 activators, " Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 4, pp. 431-437, 2009.
75. J. C. Milne, P. D. Lambert, S. Schenk et al., "Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes, " Nature, vol. 450, no. 7170, pp. 712-716, 2007.
76. S. V. De Kreutzenberg, G. Ceolotto, I. Papparella et al., "Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms, " Diabetes, vol. 59, no. 4, pp. 1006-1015, 2010.
77. G. Ramadori, L. Gautron, T. Fujikawa, C. R. Vianna, J. K. Elmquist, and R. Coppari, "Central administration of resveratrol improves diet-induced diabetes, " Endocrinology, vol. 150, no. 12, pp. 5326-5333, 2009.
78. C. D. Côté, B. A. Rasmussen, F. A. Duca et al., "Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network, " Nature Medicine, vol. 21, no. 5, pp. 498-505, 2015.
79. B. Bordone and L. Guarente, "Sirtuins and β-cell function, " Diabetes, Obesity and Metabolism, vol. 9, no. 2, pp. 23-27, 2007.
80. Y. I. Kitamura, T. Kitamura, J.-P. Kruse et al., "FoxO1 protects against pancreatic β cell failure through NeuroD and MafA induction, " Cell Metabolism, vol. 2, no. 3, pp. 153-163, 2005.
81. K. Turkmen, A. Karagoz, and A. Kucuk, "Sirtuins as novel players in the pathogenesis of diabetes mellitus, " World Journal of Diabetes, vol. 5, no. 6, pp. 894-900, 2014.
82. K. Hasegawa, S. Wakino, K. Yoshioka et al., "Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression, " Biochemical and Biophysical Research Communications, vol. 372, no. 1, pp. 51-56, 2008.
83. P. T. Pfluger, D. Herranz, S. Velasco-Miguel, M. Serrano, and M. H. Tschöp, "Sirt1 protects against high-fat diet-induced metabolic damage, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 28, pp. 9793-9798, 2008.
84. K. A. Moynihan, A. A. Grimm, M. M. Plueger et al., "Increased dosage of mammalian Sir2 in pancreatic β cells enhances glucose-stimulated insulin secretion in mice, " Cell Metabolism, vol. 2, no. 2, pp. 105-117, 2005.
85. K. M. Ramsey, K. F. Mills, A. Satoh, and S.-I. Imai, "Ageassociated loss of Sirt1-mediated enhancement of glucosestimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice, " Aging Cell, vol. 7, no. 1, pp. 78-88, 2008.
86. M. Kitada and D. Koya, "SIRT1 in type 2 diabetes: mechanisms and therapeutic potential, " Diabetes and Metabolism Journal, vol. 37, no. 5, pp. 315-325, 2013.
87. S. S. Kulkarni and C. Cantó, "The molecular targets of resveratrol, " Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1852, no. 6, pp. 1114-1123, 2015.
88. M.-J. Lee, D. Feliers, M. M. Mariappan et al., "A role for AMPactivated protein kinase in diabetes-induced renal hypertrophy, " American Journal of Physiology-Renal Physiology, vol. 292, no. 2, pp. F617-F627, 2007.
89. K.-H. Chen, C.-C. Hung, H.-H. Hsu, Y.-H. Jing, C.-W. Yang, and J.-K. Chen, "Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-β/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats, " Chemico-Biological Interactions, vol. 190, no. 1, pp. 45-53, 2011.
90. N. L. Price, A. P. Gomes, A. J. Y. Ling et al., "SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function, " CellMetabolism, vol. 15, no. 5, pp.675-690, 2012.
91. C.-C. Chang, C.-Y. Chang, J.-P. Huang, and L.-M. Hung, "Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats, " Chinese Journal of Physiology, vol. 55, no. 3, pp. 192-201, 2012.
92. R. Schmatz, L. B. Perreira, N. Stefanello et al., "Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats, " Biochimie, vol. 94, no. 2, pp. 374-383, 2012.
93. K. Carolo dos Santos, C. Pereira Braga, P. Octavio Barbanera, F. R. F. Seiva, A. Fernandes Jr., and A. A. H. Fernandes, "Cardiac energy metabolism and oxidative stress biomarkers in diabetic rat treated with resveratrol, " PLoS ONE, vol. 9, no. 7, Article ID e102775, 2014.
94. M. Kitada, S. Kume, N. Imaizumi, and D. Koya, "Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway, " Diabetes, vol. 60, no. 2, pp. 634-643, 2011.
95. S. Khamneh, F. G. Soufi, and F. Afshar, "Long-term resveratrol administration reduces renal oxidative stress and apoptosis rate in experimental model of type 2 diabetes, " Life Science Journal, vol. 9, no. 4, pp. 2997-3001, 2012.
96. H. E. Mohamed, S. E. El-Swefy, R. A. Hasan, and A. A. Hasan, "Neuroprotective effect of resveratrol in diabetic cerebral ischemic-reperfused rats through regulation of inflammatory and apoptotic events, " Diabetology & Metabolic Syndrome, vol. 6, no. 1, article 88, 2014.
97. E. Yulug, S. Tured, A. Alver, O. Kutlu, E. Karaguzel, and C. Kahraman, "Effects of resveratrol on testis damage in streptozotocin induced diabetic rats, " Journal of Animal andVeterinary Advances, vol. 12, no. 6, pp. 747-753, 2013.
98. J. Jeong, M. J. Conboy, and I. M. Conboy, "Sirt1-independent rescue of muscle regeneration by resveratrol in type I diabetes, " Journal of Diabetes & Metabolism, vol. 4, article 289, 2013.
99. M. C. Haigis and L. P. Guarente, "Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction, " Genes & Development, vol. 20, no. 21, pp. 2913-2921, 2006.
100. S. Michan and D. Sinclair, "Sirtuins in mammals: insights into their biological function, " Biochemical Journal, vol. 404, no. 1, pp. 1-13, 2007.
101. D.-W. Park, K. Baek, J.-R. Kim et al., "Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species andmonocyte chemotactic protein-1, " Experimental and Molecular Medicine, vol. 41, no. 3, pp. 171-179, 2009.
102. Z. Ungvari, N. Labinskyy, P. Mukhopadhyay et al., "Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 297, no. 5, pp. H1876-H1881, 2009.
103. L. M. Pedruzzi, M. B. Stockler-Pinto, M. Leite Jr., and D. Mafra, "Nrf2-keap1 system versus NF-κB: the good and the evil in chronic kidney disease?" Biochimie, vol. 94, no. 12, pp. 2461-2466, 2012.
104. A. A. Elmarakby and J. C. Sullivan, "Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy, " Cardiovascular Therapeutics, vol. 30, no. 1, pp. 49-59, 2012.
105. T. Lawrence, "The nuclear factor NF-κB pathway in inflammation, " Cold Spring Harbor Perspectives in Biology, vol. 1, no. 6, Article ID a001651, 2009.
106. A. Kumar andS. S. Sharma, "NF-κB inhibitory action of resveratrol: a probablemechanismof neuroprotection in experimental diabetic neuropathy, " Biochemical and Biophysical Research Communications, vol. 394, no. 2, pp. 360-365, 2010.
107. O. Prabhakar, "Cerebroprotective effect of resveratrol through antioxidant and anti-inflammatory effects in diabetic rats, " Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 386, no. 8, pp. 705-710, 2013.
108. X.-D. Lou, H.-D. Wang, S.-J. Xia, S. Skog, and J. Sun, "Effects of resveratrol on the expression and DNA methylation of cytokine genes in diabetic rat aortas, " Archivum Immunologiae et Therapiae Experimentalis, vol. 62, no. 4, pp. 329-340, 2014.
109. S.-M. Lee, H. Yang, D. M. Tartar et al., "Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes, " Diabetologia, vol. 54, no. 5, pp. 1136-1146, 2011.
110. H. Zhang, J. Zhang, Z. Ungvari, and C. Zhang, "Resveratrol improves endothelial function. Role of TNFα and vascular oxidative stress, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 8, pp. 1164-1171, 2009.
111. A. Movahed, I. Nabipour, X. L. Louis et al., "Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients, " Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 851267, 11 pages, 2013.
112. P. Brasnyó, G. A. Molnár, M. Mohás et al., "Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients, " British Journal of Nutrition, vol. 106, no. 3, pp. 383-389, 2011.
113. Y. K. Bashmakov, S. H. Assaad-Khalil, M. Abou Seif et al., "Resveratrol Promotes Foot Ulcer Size Reduction in Type 2 Diabetes Patients, " ISRN Endocrinology, vol. 2014, Article ID 816307, 8 pages, 2014.
114. S. Timmers, E. Konings, L. Bilet et al., "Calorie restrictionlike effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans, " Cell Metabolism, vol. 14, no. 5, pp. 612-622, 2011.
115. B. Agarwal, M. J. Campen, M. M. Channell et al., "Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium, " International Journal of Cardiology, vol. 166, no. 1, pp. 246-248, 2013.
116. M. M. Poulsen, P. F. Vestergaard, B. F. Clasen et al., "Highdose resveratrol supplementation in obesemen: an investigatorinitiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition, " Diabetes, vol. 62, no. 4, pp. 1186-1195, 2013.
117. S. Dash, C. Xiao, C. Morgantini, L. Szeto, and G. F. Lewis, "High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 12, pp. 2895-2901, 2013.
118. V. S. Chachay, G. A. Macdonald, J. H. Martin et al., "Resveratrol does not benefit patients with nonalcoholic fatty liver disease, " Clinical Gastroenterology and Hepatology, vol. 12, no. 12, pp. 2092-2103, 2014.
119. A. V. Witte, L. Kerti, D. S. Margulies, and A. Flöel, "Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults, " The Journal of Neuroscience, vol. 34, no. 23, pp. 7862-7870, 2014.
120. M. M. Shahi, F. Haidari, andM. R. Shiri, "Comparison of effect of resveratrol and vanadium on diabetes related dyslipidemia and hyperglycemia in streptozotocin induced diabetic rats, " Advanced Pharmaceutical Bulletin, vol. 1, no. 2, pp. 81-86, 2011.
121. A.-S. Cheng, Y.-H. Cheng, C.-Y. Lee, C.-Y. Chung, and W.-C. Chang, "Resveratrol protects against methylglyoxal-induced hyperglycemia and pancreatic damage in vivo, " Nutrients, vol. 7, no. 4, pp. 2850-2865, 2015.
122. S. Pereira, E. Park, J. Moore et al., "Resveratrol prevents insulin resistance caused by short-term elevation of free fatty acids in vivo, " Applied Physiology, Nutrition andMetabolism, vol. 40, no. 11, pp. 1129-1136, 2015.
123. J. Burns, T. Yokota, H. Ashihara, M. E. J. Lean, and A. Crozier, "Plant foods and herbal sources of resveratrol, " Journal of Agricultural and Food Chemistry, vol. 50, no. 11, pp. 3337-3340, 2002.
124. C. Counet, D. Callemien, and S. Collin, "Chocolate and cocoa: new sources of trans-resveratrol and trans-piceid, " Food Chemistry, vol. 98, no. 4, pp. 649-657, 2006.
125. W. J. Hurst, J. A. Glinski, K. B. Miller, J. Apgar, M. H. Davey, and D. A. Stuart, "Survey of the trans-resveratrol and trans-piceid content of cocoa-containing and chocolate products, " Journal of Agricultural and Food Chemistry, vol. 56, no. 18, pp. 8374-8378, 2008.
126. S. Mukherjee, J. I. Dudley, andD. K. Das, "Dose-dependency of resveratrol in providing health benefits, " Dose-Response, vol. 8, no. 4, pp. 478-500, 2010.
127. Y. K. Bashmakov, S. Assaad-Khalil, and I. M. Petyaev, "Resveratrol may be beneficial in treatment of diabetic foot syndrome, " Medical Hypotheses, vol. 77, no. 3, pp. 364-367, 2011.
128. J. Tomé-Carneiro, M. Larrosa, M. J. Yáñez-Gascón et al., "One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease, " Pharmacological Research, vol. 72, pp. 69-82, 2013.
129. J. Yoshino, C. Conte, L. Fontana et al., "Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance, " CellMetabolism, vol. 16, no. 5, pp. 658-664, 2012.
130. J. P. Crandall, V. Oram, G. Trandafirescu et al., "Pilot study of resveratrol in older adults with impaired glucose tolerance, " The Journals of Gerontology Series A: Biological Sciences andMedical Sciences, vol. 67, no. 12, pp. 1307-1312, 2012.
131. C. Militaru, I. Donoiu, A. Craciun, I.D. Scorei, A. M. Bulearca, and R. I. Scorei, "Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life, " Nutrition, vol. 29, no. 1, pp. 178-183, 2013.
132. J. Tomé-Carneiro, M. Gonzálvez, M. Larrosa et al., "One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease, " American Journal of Cardiology, vol. 110, no. 3, pp. 356-363, 2012.
133. T. Walle, M.H. De Legge, R. E. Hypolite, J. T. Lucas, and U. K. Walle, "Resveratrol-[C-14] disposition and metabolism in vivo in humans, " The FASEB Journal, vol. 18, no. 4, p. A604, 2004.
134. J. M. Smoliga and O. Blanchard, "Enhancing the delivery of resveratrol in humans: if lowbioavailability is the problem, what is the solution?" Molecules, vol. 19, no. 11, pp. 17154-17172, 2014.
135. E. L. Wightman, J. L. Reay, C. F. Haskell, G. Williamson, T. P. Dew, and D. O. Kennedy, "Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation, " British Journal of Nutrition, vol. 112, no. 2, pp. 203-213, 2014.
136. H. J. Park, J.-Y. Yang, S. Ambati et al., "Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes, " Journal of Medicinal Food, vol. 11, no. 4, pp. 773-783, 2008.
137. A. Schlachterman, F. Valle, K. M. Wall et al., "Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in a nude mousemodel, " Translational Oncology, vol. 1, no. 1, pp. 19-27, 2008.
138. S. Rayalam, M. A. Della-Fera, and C. A. Baile, "Synergism between resveratrol and other phytochemicals: implications for obesity and osteoporosis, "MolecularNutrition & Food Research, vol. 55, no. 8, pp. 1177-1185, 2011.
139. C. K. Singh, J. George, and N. Ahmad, "Resveratrol-based combinatorial strategies for cancer management, " Annals of the New York Academy of Sciences, vol. 1290, no. 1, pp. 113-121, 2013.
140. K.R. Polley, N. Jenkins, P.O'Connor, and K. McCully, "Influence of exercise trainingwith resveratrol supplementation on skeletal muscle mitochondrial capacity, " Applied Physiology, Nutrition and Metabolism, vol. 41, no. 1, pp. 26-32, 2015.
141. C. Chu, F. J. Lu, R.H. Yeh, Z. L. Li, and C.H. Chen, "Synergistic antioxidant activity of resveratrol with genistein in high-glucose treatedMadin-Darby canine kidney epithelial cells, " Biomedical Reports, vol. 4, no. 3, pp. 349-354, 2016.
142. R. L. Frozza, A. Bernardi, K. Paese et al., "Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats, " Journal of Biomedical Nanotechnology, vol. 6, no. 6, pp. 694-703, 2010.
143. L. Liang, X. Liu, Q. Wang, S. Cheng, S. Zhang, and M. Zhang, "Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3, 5, 4'-tri-O-acetylresveratrol in rats, " Phytomedicine, vol. 20, no. 6, pp. 558-563, 2013.